An AFP-L3% assay might provide better information about future disease recurrence/relapse for NSGCT, teratocarcinoma and embryonal cell carcinoma adult patients than the AFP level in serum, as suggested by Kawai et al. [107]. This evidence concerns the gene AFP and nongerminomatous germ cell tumor.